like it-fall somewhat across the diagnostic boundaries lying between genuine eosinophilic leukaemia, and eosinophilic collagen disease. These two conditions may be extremes of a single spectrum caused by a basic single underlying cause as yet unknown. We would propose that a descriptive title should be used to avoid unintentional categorization, such as idiopathic eosinophilic leukaemoid reaction. The relation of the terminal diffuse intravascular thrombotic process to the initial disease process is obscure.
The role, if any, of the intracellular virus-like particle, seen only in the nucleus of one eosinophil is quite unknown. There were no pathological features of encephalitis. As (Brunner et al., 1972) . Adequate therapy for the condition is difficult to assess clinically as the major therapeutic agents, including streptomycin, sodium aminosalicylate (PAS), isoniazid and ethambutol, are normally excreted in the urine (Welch, 1954) and produce important toxic effects if blood levels become elevated. Thus, in oliguric or anuric patients, safe and effective therapy is possible only when the blood levels of these drugs are routinely measured.
Rifampicin, however, is excreted in the bile and does not accumulate in the serum of anuric patients (Spring, 1968 Bratton and Marshall (1939) mg/100 ml; this exceeds the therapeutic range defined by Emerson and Kuper (1964) . PAS dosage was accordingly reduced to 4-5 g daily and satisfactory serum levels of between 2 mg/100 ml and 4-5 mg/100 ml before dialysis were recorded. Serum rifampicin levels measured before dialysis by a bioassay method using Sarcina lutea as the test organism (Jeannes, Jessamine and Eidus, 1972) were between 3-75 ,ig/ml and 4 tg/ml and thus were within the therapeutic range (Spring, 1968) . The M. tuberculosis cultured from the sputum was shown in vitro to be sensitive to all the commonly prescribed agents but was particularly sensitive to rifampicin. Two months after commencing treatment, the patient developed severe diarrhoea, PAS and isoniazid were withdrawn, treatment was continued with rifampicin alone and the diarrhoea gradually improved. As the reintroduction of PAS coincided with a further exacerbation of the gastrointestinal symptoms, treatment with this drug was finally discontinued and the patient experienced no further bowel upset. At this time, however, a pericardial effusion was detected (Fig. 2) (Fig. 3) and acid-fast bacilli have not been isolated from the sputum during the past 12 months. The patient now undertakes his own haemodialysis at home thrice weekly and continues on rifampicin 450 mg daily. 
Discussion
The treatment of pulmonary tuberculosis in patients on maintenance haemodialysis is complicated by the potential toxicity of the commonly prescribed anti-tuberculous drugs. Streptomycin, which is largely excreted in the urine (Welch, 1954) , has been reported to produce vestibular damage in a patient on haemodialysis at a time when serum levels of the drug were not elevated and when a total dose of only 11 g had been administered (Ogg, Toseland and Cameron, 1969 (Garrod and O'Grady, 1971) ; indeed it has been suggested (Wechsler, 1971) that not only should blood levels of the drug be monitored routinely but also that all patients should have complete eye examinations before and during treatment. As excretion is by the kidneys (Wechsler, 1971) (Bowersox et al., 1973) . However, as the phenotype cannot be definitely established in patients with renal failure, these patients should be considered to be 'slow acetylators' and the dose of isoniazid reduced accordingly (Bowersox et al., 1973) . PAS, however, although not a potent drug, is excreted mainly by the kidneys, and is an acceptable therapy, provided that the daily dosage is reduced and blood levels routinely monitored (Ogg et al., 1969) .
Rifampicin has none of these toxic effects and may be given in normal dosages (450-600 mg daily) to patients with impaired renal function. The drug is excreted mainly in the bile and abnormalities of liver function tests have been reported after prolonged use (Jeannes et al., 1972; Lees, 1970 (Canetti, 1968) and although the proportion of strains resistant to rifampicin is low (Grumbach and Rist, 1967) 
